Age-Related Difference in the Sleep Pressure-Lowering Effect Between an XXXX Receptor Blocker and a @entity460 Channel Blocker in Asian Hypertensives: The ACS1 Study.

@entity1 @entity101 @entity2178 @entity6290 @entity3591 @entity460 @entity551
UNASSIGNED: Sleep blood pressure (BP), which is partly determined by salt sensitivity and intake, is an important cardiovascular risk in @entity101 . However, there have been no studies on age-related differences in the sleep BP-lowering effect between @entity2178 receptor blockers and @entity460 channel blockers in Asians. @entity6290 Circadian and Sleep Pressure-the 1st Study was a multicenter, randomized, open-label, 2-parallel-group study conducted to compare the efficacy of 8-week oral treatment with an @entity2178 receptor blocker ( @entity6290 20 mg) or a @entity460 channel blocker ( @entity3591 5 mg) on sleep BP as evaluated by ambulatory BP monitoring. Among the overall population, @entity3591 treatment achieved significantly greater @entity551 , awake BP, and 24-hour BP than @entity6290 treatment. BP reduction by @entity3591 was particularly pronounced in elderly @entity101 @entity1 aged >= 60 years old. Among @entity1 >= 60 years old, the @entity3591 group had numerically, but not significantly, higher control rate of sleep BP compared with the @entity6290 group. Similar results were found for awake BP and 24-hour BP. These results suggest a greater BP reduction/control by @entity3591 compared with @entity6290 and that reduction/control of BP by @entity3591 was also more effective in the elderly population. As recommended in the American Society of @entity101 /The international Society of @entity101 and the National Institute for Health and Clinical Excellence guidelines for differentiating treatment according to age, @entity3591 should be one of the options for starting treatment in the elderly population. CLINICAL TRIAL URL: http://clinicaltrials.gov/show/NCT01762501 CLINICAL TRIAL ID: NCT01762501.
